Importantly, treatment with ASO improved the in vivo persistence of transferred cells in KRAS mutant tumors (Figure 6J,K), and thus a combination of ASO and adoptive transfer with tumor‐reactive T‐cells significantly inhibited tumor growth (Figure 6L,M). This evidence concerns the gene KRAS and neoplasm.